Neuroderm ltd
Neuroderm ltd is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Neuroderm ltd.
Neuroderm ltd is a company.
Key people at Neuroderm ltd.
NeuroDerm Ltd. is a clinical-stage pharmaceutical company based in Rehovot, Israel, specializing in treatments for central nervous system (CNS) disorders, particularly Parkinson's disease.[1][2] It develops innovative product candidates like ND0612, a subcutaneous levodopa/carbidopa (LD/CD) formulation for continuous drug delivery to improve dopamine levels and alleviate motor symptoms in Parkinson's patients, and ND0701, a subcutaneous apomorphine formulation for moderate to severe cases.[1][2] The company also explores therapies for cognition disorders in conditions like ADHD, Alzheimer's, and schizophrenia, serving patients with advanced CNS diseases who face limitations from oral treatments.[1][2] As a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation since October 2017, NeuroDerm integrates pharmaceutical formulations with MedTech delivery systems and digital health solutions, driving patient-centric innovation with around 165 employees and reported revenue of $9.1 million.[1][2]
Founded in 2003 in Rehovot, Israel, NeuroDerm emerged as an agile R&D company focused on addressing deficiencies in CNS treatments through novel administration routes for existing drugs.[1][2] The company's early efforts centered on continuous, controlled delivery technologies to enhance clinical efficacy, culminating in Phase II completion for ND0612L by around 2014 and ongoing advanced trials.[5][2] A pivotal moment came in October 2017 when it became a subsidiary of Mitsubishi Tanabe Pharma Corporation, providing resources for Phase 3 trials like the BouNDless study and its open-label extension, which demonstrated long-term efficacy in Parkinson's motor control.[1][2]
NeuroDerm rides the wave of precision neurology and continuous drug delivery trends, addressing the growing prevalence of Parkinson's disease amid an aging global population and limitations of intermittent oral therapies.[1][2] Its timing aligns with advances in MedTech wearables and subcutaneous pumps, enabling better symptom management and influencing the shift toward integrated pharma-digital solutions in CNS care.[2][3][4] Market forces like rising demand for non-oral Parkinson's treatments—projected to expand with demographic shifts—favor its subcutaneous platforms, while its subsidiary status amplifies Mitsubishi Tanabe's global reach, contributing to ecosystem-wide innovations in neurodegenerative therapies.[1][2]
NeuroDerm is poised for potential regulatory approvals and commercialization of ND0612, building on Phase 3 successes, with next steps likely including expanded indications and digital enhancements for real-world monitoring.[2] Trends like AI-driven personalization in neurology and subcutaneous delivery adoption will shape its trajectory, potentially evolving its influence through partnerships that scale CNS innovations globally. This positions the company to transform Parkinson's management, echoing its founding mission of overcoming treatment deficiencies through smart delivery.[1][2][4]
Key people at Neuroderm ltd.
